Partner Description
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
The Nonclinical Drug Safety department located in Ridgefield, CT, USA, will be leading Boehringer Ingelheim’s contributions to the imSAVAR project.
Role within Project
- Performance of patient-derived versus healthy volunteer derived CRAs for diverse drug-induced mechanisms
- Contributing to irAOP generation
- Select suitable in vitro cell culture assays, perform these assays, analyze CR and immune cell activation
- Profiling of human and cross species comparative transcriptomic analysis of immune cell in support of biomarker discovery
- Part of managing board